A 28-year-old woman from Delhi presents with severe headache, fever (39.2°C), and neck stiffness for 2 days. CSF analysis shows elevated protein (180 mg/dL), low glucose (25 mg/dL), and pleocytosis with predominant PMNs. Blood culture grows Neisseria meningitidis. She is started on ceftriaxone and vancomycin. On day 3 of therapy, despite appropriate dosing and CSF penetration, her CSF glucose remains low and she develops seizures. The clinical team suspects inadequate bacterial killing. Which type of enzyme inhibition is MOST likely preventing optimal penicillin-binding protein (PBP) inhibition in this resistant strain?

Explanation

## Enzyme Inhibition in Antibiotic Resistance ### Mechanism of β-Lactam Action Penicillins and cephalosporins act as **structural analogs of D-Ala-D-Ala**, the natural substrate of penicillin-binding proteins (PBPs). They competitively occupy the active site of PBP, inhibiting transpeptidation and peptidoglycan cross-linking. This is the basis of **competitive inhibition** of PBP by β-lactam antibiotics. ### Why Altered PBP = Competitive Inhibition (Correct Answer: B) **Key Point:** In resistant *Neisseria meningitidis*, mutations in genes encoding PBPs (e.g., *penA*, *ftsI*) produce **altered PBPs with reduced affinity** for β-lactams. The antibiotic still competes for the same active site as D-Ala-D-Ala, but the higher Km (lower affinity) means the drug is less effective at normal concentrations. This is the **hallmark of competitive inhibition** — the enzyme is structurally present and functional, but the inhibitor binds with reduced potency. **Clinical Pearl:** Competitive inhibition can be overcome by increasing inhibitor (antibiotic) concentration — which is why high-dose cephalosporins are used in resistant meningitis. This distinguishes it from non-competitive inhibition, where increasing drug concentration does NOT restore efficacy. ### Why the Other Options Are Incorrect | Option | Mechanism | Why Wrong Here | |---|---|---| | **A) β-Lactamase (Non-competitive)** | Destroys antibiotic before PBP binding | *N. meningitidis* rarely produces β-lactamase; the stem specifies adequate CSF penetration, implying drug reaches PBP intact | | **C) Ribosomal methylation (Uncompetitive)** | Targets ribosome, not PBP | Irrelevant to PBP inhibition; this is a macrolide/aminoglycoside resistance mechanism | | **D) Efflux pumps (Mixed-type)** | Reduces intracellular drug | Efflux pumps reduce drug concentration but do not directly alter PBP affinity; not the primary mechanism in meningococcal resistance | ### Why This Case Points to Altered PBP - **Adequate CSF penetration** is explicitly stated — drug is reaching the target - **Ceftriaxone + vancomycin** are both used, suggesting β-lactam resistance (not absence of drug) - *N. meningitidis* resistance in clinical settings is predominantly mediated by **PBP mutations** (reduced penicillin affinity), not β-lactamase production (which is rare and plasmid-mediated) - Seizures on day 3 with persistent low CSF glucose indicate **suboptimal bacterial killing despite drug presence** — consistent with reduced drug-enzyme affinity ### Lineweaver-Burk Interpretation In competitive inhibition: **Vmax unchanged, Km increased**. The inhibitor (antibiotic) and natural substrate (D-Ala-D-Ala) compete for the same active site of PBP. Increasing antibiotic dose can overcome this — the rationale for salvage therapy in resistant meningitis. **High-Yield (KD Tripathi / Jawetz Microbiology):** Altered PBPs cause **competitive inhibition** because the enzyme still exists and binds substrate at the same site, but with reduced affinity. β-Lactamase causes substrate destruction (non-competitive in effect), but this is NOT the mechanism described in this vignette given adequate drug penetration and the epidemiology of *N. meningitidis* resistance.